<DOC>
	<DOC>NCT00552188</DOC>
	<brief_summary>The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.</brief_summary>
	<brief_title>Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event</brief_title>
	<detailed_description>The effect of VIA-2291 on vascular inflammation will be assessed through 18FDG PET vascular imaging measurements and various biomarkers after 24 weeks.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Lipoxygenase Inhibitors</mesh_term>
	<mesh_term>Atreleuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Inclusion Criteria Female patients must be of nonchildbearing potential Recent acute coronary syndrome [(ACS) ST elevation myocardial infarction (STEMI), nonSTEMI or unstable angina) event documented by ECG, cardiac enzymes or angiogram] 1 3 months prior to randomization Carotid or ascending aorta artery plaque inflammation TargettoBackground Ratio (TBR) â‰¥ 1.6 Receiving concomitant statin therapy following the qualifying ACS event for a minimum of 4 weeks, including a stable statin dose regimen for 2 weeks prior to randomization. Exclusion Criteria Renal insufficiency defined as creatinine &gt;1.5 x upper limit of normal (ULN) Cirrhosis, recent hepatitis, alanine aminotransferase (ALT) &gt;1.5 x ULN (i.e., above the normal range) or positive screening test for hepatitis B (hepatitis B surface antigen) or hepatitis C (by ELISA) Type I diabetes and uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) &gt; 9% Heart failure defined by New York Heart Association Class III or IV Coronary Artery Bypass Surgery (CABG) within 4 months of randomization Use of zileuton, montelukast, coumadin or steroids Acetaminophen use in any form in the 7 days before enrollment at Visit 1 Allergy to contrast agents Planned additional cardiac intervention (e.g., PCI, CABG) within next 6 months Current atrial fibrillation, atrial flutter or frequent premature ventricular contractions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Atherosclerosis</keyword>
</DOC>